A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.
Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, the company’s SVP of finance.
Australian researchers said the virus that causes Covid-19 can survive on banknotes, glass and stainless steel for up to 28 days, much longer than the flu virus, highlighting the need for frequent cleaning and handwashing.
Acasti Pharma announced topline data from the company’s Phase III TRILOGY 2 trial of CaPre (omega-3 phospholipid) to reduce severe triglyceride levels.
Shares of Akcea Therapeutics were up more than 60 percent in trading after majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24 percent of available stock for $18.50 per share.
A review of some recently published scientific studies includes one for antihistamines and similar compounds that might slow down Huntington’s disease.
BioSpace reviews some recently published scientific studies, including researchers with the University of Colorado Anschutz Medical Campus releasing a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa.
Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.
Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.